Wegovy

The brand name for semaglutide 2.4 mg weekly subcutaneous injection, approved by the FDA in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Manufactured by Novo Nordisk. STEP clinical trial program demonstrated average weight loss of approximately 14.9–17.4% of body weight over 68 weeks — the highest for any approved GLP-1 receptor agonist monotherapy prior to tirzepatide.